Stock AIM AIM IMMUNOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Market Closed - Nyse
Other stock markets
 01:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
0.3799 USD -2.84% Intraday chart for AIM ImmunoTech Inc. -4.38% -13.64%
05/06 Transcript : AIM ImmunoTech Inc. - Special Call
16/05 Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
GL
Transcript : AIM ImmunoTech Inc. - Special Call
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
GL
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
GL
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
GL
Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
GL
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
GL
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
MT
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GL
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GL
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
GL
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
CI
Challenges To Advance Notice Bylaws Are Spiking
AQ
Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AIM Stock
  4. News AIM ImmunoTech Inc.